Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Chemicals

Celanese Announces Price Adjustments for Key Polymer Products

Robert Sasse by Robert Sasse
January 26, 2026
in Chemicals, Earnings, Industrial
0
Celanese Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

The specialty materials company Celanese has confirmed a series of price increases for its polyamide products, set to take effect in the Americas and EMEA regions. This strategic move, attributed to rising energy and raw material expenses, coincides with several other significant corporate developments, including an upcoming earnings release and a key sustainability achievement.

Key Developments at a Glance

  • Price Increase Effective Date: February 1, 2026
  • Polyamide‑6 Adjustment: +$0.25 per kg (Americas), +€0.25 per kg (EMEA)
  • Polyamide‑6,6 Adjustment: +$0.20 per kg (Americas), +€0.20 per kg (EMEA)
  • Q4 2025 Earnings: Press release scheduled for February 17, 2026, after U.S. market close; conference call to follow on February 18, 2026.
  • Sustainability Certification: ISCC Carbon Footprint Certification awarded on December 9, 2025, for select POM ECO grades.
  • Board Change: Director Scott Sutton resigned from the board, effective January 6, 2026.

Strategic Pricing Response to Market Pressures

Citing elevated costs for energy and feedstock, Celanese will implement new pricing across its polyamide portfolio. Beginning February 1, 2026, the increase will apply to products sold under brands including Zytel, Frianyl, Celanyl, Minlon, CoolPoly, and Ecomid.

In the Americas, the price for Polyamide‑6 will rise by $0.25 per kilogram, while in Europe, the Middle East, and Africa (EMEA), the increase will be €0.25 per kilogram. For Polyamide‑6,6 products under the same brand families, the adjustment will be $0.20 per kg in the Americas and €0.20 per kg in EMEA. The firm emphasized that its regional supply chains and manufacturing capabilities are positioned to maintain customer support throughout this transition.

Should investors sell immediately? Or is it worth buying Celanese?

Sustainability Milestone and Board Update

In a separate announcement, Celanese received an ISCC Carbon Footprint Certification (CFC) for its Hostaform® and Celcon® POM ECO‑C‑Grade materials. The certification, granted on December 9, 2025, covers production at the company’s facilities in Frankfurt, Germany, and Bishop, Texas. This achievement is linked to investments in Carbon Capture and Utilization (CCU) technology through the Fairway Methanol Joint Venture in Clear Lake, Texas, which aims to lower the carbon footprint of its products.

The company also confirmed a change in its board composition. Scott Sutton stepped down from his director role on January 6, 2026. Celanese stated that his departure was due to his appointment as Chief Executive Officer of another organization.

Upcoming Financial Disclosure

Market participants will gain further insight into the company’s performance when Celanese reports its fourth-quarter 2025 results. The financial figures will be released after the close of U.S. markets on February 17, 2026. Management will host a conference call to discuss the quarterly performance the following day, February 18. This earnings report is anticipated to provide clarity on how recent operational factors, including the newly announced pricing strategy, have influenced revenue and margin trends in the final quarter of the year.

Ad

Celanese Stock: Buy or Sell?! New Celanese Analysis from February 8 delivers the answer:

The latest Celanese figures speak for themselves: Urgent action needed for Celanese investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Celanese: Buy or sell? Read more here...

Tags: Celanese
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

DroneShield Stock
Analysis

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Next Post
Healwell AI Stock

Regulatory Scrutiny Tempers Healwell AI's Growth Narrative

Nvidia Stock

Nvidia's Strategic Bet: Doubling Down on AI Infrastructure

Netflix Stock

Netflix Shares Surge on Robust Quarterly Performance and Ambitious Outlook

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com